SARS-CoV-2-Host Interactions: Implications for Secondary Bacterial Co-infections [Funder: Carleton University COVID-19 Rapid Research Response Grants]

Respiratory viral infections - including human corona viruses - have been shown to predispose patients to bacterial co-infections, which can lead to increased disease severity and mortality. Up to 50% of patients with COVID-19 pneumonia have secondary bacterial infections, but it is unclear if these super infections contribute to disease. In this study, we will use in vitro and in vivo models to investigate if and how SARS-CoV-2 (causative agent of COVID-19) reprograms host immune responses to bacteria. We will also evaluate if this reprogramming drives excessive inflammation and increased lung destruction and damage. These studies will provide critical insights into the ability of SARS-CoV-2 to modulate the host immune responses and may identify new opportunities to inhibit inflammatory damage and prevent the development of secondary bacterial pneumonias in those most at risk.